Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2022-10-25 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
第三届监事会第十五次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the review and approval of the company's 2022 third quarter report. It includes details about the meeting, attendance, and voting results. The document does not contain the actual financial statements or substantive financial data of the quarterly report itself but rather confirms the approval of the report. The document length is short (1054 characters) and it references the third quarter report being published on the Beijing Stock Exchange website with a separate announcement number. This fits the pattern of a Regulatory Filing (RNS) as it is an official announcement related to the report but not the report itself. Therefore, the correct classification is Regulatory Filings (RNS).
2022-10-25 Chinese
关于回购股份注销完成暨股份变动公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the completion of a share repurchase and cancellation, including details about the number of shares repurchased, the impact on share capital, and subsequent changes in shareholding structure. It also mentions legal opinions and confirmations from relevant authorities. The content focuses on share buyback and cancellation activities rather than financial results, management changes, or regulatory filings. Therefore, it fits the category of Transaction in Own Shares (POS). The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS.
2022-10-23 Chinese
关于确定2022年度审计机构项目质量控制复核人的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the appointment and information about the project quality control reviewer for the 2022 audit firm of Jiangsu Deyuan Pharmaceutical Co., Ltd. It discusses the auditor's independence, integrity, and background, but does not contain any audit report itself or detailed financial statements. The document is short (1283 characters) and serves as a formal disclosure about the auditor's quality control reviewer, which aligns with audit-related information but is not the audit report itself. Therefore, it fits best under Audit Report / Information (AR), which includes standalone audit reports and related audit information such as quality control reviewer announcements. FY 2022
2022-10-23 Chinese
董事辞职公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a board director, Zhang Caixia, from Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the resignation date, reasons, and the impact on the company's board composition and operations. There is no financial data, no mention of financial results, reports, or regulatory filings beyond the resignation notice. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2022-10-17 Chinese
2022年上半年募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the use and management of funds raised by the company through a public stock issuance. It includes specifics on the amount raised, timing, usage of funds, current balances, changes in fund usage, and compliance with relevant laws and regulations. The document references approvals from regulatory bodies, board and shareholder meetings, and provides a comprehensive update on the status of the raised funds. This matches the characteristics of a specialized report on the use of raised capital, which aligns with the category 'Capital/Financing Update (CAP)'. The document is not a general annual or interim report, nor is it an announcement or a brief summary. It contains substantive financial and operational details about fundraising and fund usage, confirming it is a Capital/Financing Update.
2022-08-18 Chinese
国浩律师（南京）事务所关于江苏德源药业股份有限公司2022年第三次临时股东大会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a legal opinion letter issued by a law firm regarding the convening, attendance, voting procedures, and results of the 2022 third extraordinary general meeting of shareholders of Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the legality and validity of the meeting procedures and resolutions. The document is not a report of financial results, audit, or management discussion, but a legal opinion on the shareholder meeting process and outcomes. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results and confirms the validity of the shareholder meeting resolutions.
2022-08-18 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.